Effect of the third dose of BNT162b2 vaccine in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare workers
Preprint
Abstract
Background Vaccination is our main strategy to control SARS-CoV-2 infection. Given a decrease in the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months following the second BNT162b2 dose, healthcare workers got a third booster dose after six months of completing the original scheme. This study aimed to analyze quantitative SARS-CoV-2 spike 1-2 IgG antibody titers and safety of the third dose. Material and methods A prospective longitudinal cohort study included healthcare workers who received a third booster dose after six months of the complete BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers 21-28 days after the first and second dose, three months after the complete scheme, 1-7 days following the third dose, and 21-28 days after the boost. Results The cohort comprised 168 non-immunocompromised participants of 41(10) years old, 67% being women. The third dose was associated with increasing the quantitative antibody titers, regardless of previous SARS-CoV-2 history. In negative SARS-CoV-2 history, the median (IQR) antibody titers increased from 379 (645.4) to 2960 (2010), while in positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080). The third dose had less number of total side effects compared to the other two shots. The most common side effect after the third BNT162b2 shot was pain at the injection site (n=82, 84.5%), followed by tiredness (n=45, 46.4%), with a mild severity (n=36, 37.1%). Tiredness, myalgias, arthralgias, fever, and adenopathy were proportionally higher following the third dose than the two-dose regimen (pConclusion The third dose applied after six months of the original BNT162b2 regimen provided a good humoral immune response by elevating the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated with no severe side effects after the additional BNT162b2 dose.Keywords
All Related Versions
- Published version: PLOS ONE, 17 (3), e0263942.
This publication has 11 references indexed in Scilit:
- Evaluation of spike protein antigens for SARS-CoV-2 serologyJournal of Virological Methods, 2021
- Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adultsClinical Microbiology and Infection, 2021
- Total Anti-SARS-CoV-2 Antibodies Measured 6 Months After Pfizer-BioNTech COVID-19 Vaccination in Healthcare WorkersSSRN Electronic Journal, 2021
- Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experienceThe Journal of Heart and Lung Transplantation, 2021
- Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessaryJournal of Infection, 2021
- Antibody Titers 3-Months Post-Vaccination with the Pfizer/Biontech Vaccine in GreeceSSRN Electronic Journal, 2021
- Immunological mechanisms of vaccine-induced protection against COVID-19 in humansNature Reviews Immunology, 2021
- Antibody titres decline 3-month post-vaccination with BNT162b2Emerging Microbes & Infections, 2021
- Pfizer: The miracle vaccine for COVID-19?Public Health in Practice, 2020
- The STROBE guidelinesSaudi Journal of Anaesthesia, 2019